Guardant, Colorectal Cancer

Guardant, Colorectal Cancer

Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode (ECLIPSE)

Associated condition: Colorectal cancer

Status: Currently enrolling

Brief summary: This is a prospective, observational multi-site study without randomization to assess the performance characteristics of a blood-based ctDNA LUNAR-2 test to detect colorectal cancer in a screen-relevant, average risk population of participants ranging in age from 65 years to 84 years. An estimated 10,000 participants would undergo a blood draw for ctDNA LUNAR-2 testing prior to colonoscopy.

Primary objectives: To assess the performance characteristics of a blood-based ctDNA LUNAR-2 test to detect colorectal cancer in a screen-relevant, average risk population who would normally undergo invasive colonoscopy.

Estimated length of study: The Estimated Study Completion Date is January 1, 2024

For more detailed information on this research trial, including eligibility and study design, please visit the clinical trial page at U.S. National Library of Medicine’s website. Note you can submit your information for consideration by submitting the contact form on this page.

Submit Your Information for Consideration

HIPAA COMPLIANT FORM

Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode (ECLIPSE)

Associated condition: Colorectal cancer

Status: Currently enrolling

Brief summary: This is a prospective, observational multi-site study without randomization to assess the performance characteristics of a blood-based ctDNA LUNAR-2 test to detect colorectal cancer in a screen-relevant, average risk population of participants ranging in age from 65 years to 84 years. An estimated 10,000 participants would undergo a blood draw for ctDNA LUNAR-2 testing prior to colonoscopy.

Primary objectives: To assess the performance characteristics of a blood-based ctDNA LUNAR-2 test to detect colorectal cancer in a screen-relevant, average risk population who would normally undergo invasive colonoscopy.

Estimated length of study: The Estimated Study Completion Date is January 1, 2024

For more detailed information on this research trial, including eligibility and study design, please visit the clinical trial page at U.S. National Library of Medicine’s website. Note you can submit your information for consideration by submitting the contact form on this page.

Submit Your Information for Consideration

The physicians at Digestive Healthcare of Georgia are closely monitoring the coronavirus (COVID-19) outbreak. In the interest of everyone’s health and safety we ask all patients and their guests who have a fever (100° or above), symptoms of a respiratory infection, or who may have traveled to a restricted country or may have been exposed to a person with known COVID-19, the flu or any other communicable disease to reschedule their appointments or procedures. You will not be charged for canceling/rescheduling your appointment. We will be following CDC and Georgia Department of Public Health’s recommendations for screening and management of patients. If you are at all concerned you may have a serious infectious disease, your best course of action is to seek care at your primary care physician’s office or local hospital’s emergency department.

We have implemented a telemedicine visit for our patients who are unable to be in the office for their appointment. Please call our office to schedule a telemedicine visit with your provider.